Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Waidmann

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
United European Gastroenterology Journal|March 28, 2020
Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer researchFriederike Weise, Michael Vieth, Dirk Reinhold, et al.
Liver Cancer|August 20, 2021
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life CohortFabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 9, 2022
Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective StudyPeter Hunyady, Lea Streller, Darius F Rüther, et al.
Cancers|December 11, 2022
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter ExperienceFriedrich Sinner, Matthias Pinter, Bernhard Scheiner, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
Liver Cancer|August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudySabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Cell Death & Disease|October 18, 2020
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerAnna-Lena Scherr, Andreas Mock, Georg Gdynia, et al.
Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
United European Gastroenterology Journal|March 28, 2020
Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer researchFriederike Weise, Michael Vieth, Dirk Reinhold, et al.
Liver Cancer|August 20, 2021
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life CohortFabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 9, 2022
Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective StudyPeter Hunyady, Lea Streller, Darius F Rüther, et al.
Cancers|December 11, 2022
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter ExperienceFriedrich Sinner, Matthias Pinter, Bernhard Scheiner, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
Liver Cancer|August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudySabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Cell Death & Disease|October 18, 2020
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerAnna-Lena Scherr, Andreas Mock, Georg Gdynia, et al.
Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
Pageof 12